Chris Bostick

Chris Bostick

Partner

Chris is passionate about technologies using interdisciplinary approaches to enable precision medicine.

He focuses on healthcare investments at OCV and Co-led investments including Rad AI and TORL Biotherapeutics. Most recently he was selected to the Milken Institute Young Leaders Circle in 2024 and has been recognized by Biocom in 2021 as one of ten life science trailblazers under 40. Prior to OCV, Dr. Bostick completed postdoctoral work at the Institute for Genomic Medicine at Columbia University where he researched precision medicine-based approaches for treating genetic neurological disorders. Prior to that, he researched drug metabolism, bioelectronics/biosensors, and nanotechnology for his Ph.D. Dr. Bostick holds a B.S. in Biology with a minor in Business from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University where he was an NSF IGERT Fellow.

Chris serves as a Board Member for the following portfolio companies:

  • Rad AI
  • Ossio (Observer)
  • TORL (Observer)

With our decades of company building experience, we look to create asymmetric advantages when backing winning teams.